Volume 138, Issue 1, Pages 123-135.e2 (January 2010) Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection  Gregory J. Dore, Margaret Hellard, Gail V. Matthews, Jason Grebely, Paul S. Haber, Kathy Petoumenos, Barbara Yeung, Philippa Marks, Ingrid van Beek, Geoffrey McCaughan, Peter White, Rosemary French, William Rawlinson, Andrew R. Lloyd, John M. Kaldor  Gastroenterology  Volume 138, Issue 1, Pages 123-135.e2 (January 2010) DOI: 10.1053/j.gastro.2009.09.019 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Overview of study population. At least 1 dose of PEG-IFN was administered to 111 participants. Two HCV/HIV coinfected participants received PEG-IFN monotherapy (both nonresponders) before a protocol amendment in which HCV/HIV participants then received PEG-IFN and ribavirin combination therapy. Gastroenterology 2010 138, 123-135.e2DOI: (10.1053/j.gastro.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Overview of HCV mono-infected participant population. Gastroenterology 2010 138, 123-135.e2DOI: (10.1053/j.gastro.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Response rates in (A) HCV mono-infected participants and (B) HCV/HIV co-infected participants in the total study population (intent-to-treat) and per-protocol population. Gastroenterology 2010 138, 123-135.e2DOI: (10.1053/j.gastro.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 Time to HCV-RNA clearance among treated and untreated participants in the ATAHC study. Gastroenterology 2010 138, 123-135.e2DOI: (10.1053/j.gastro.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 1 Adherence to PEG-IFN by the number of total PEG-IFN alfa-2a injections received in HCV (n = 74) and HCV/HIV infected (n = 35) participants. Gastroenterology 2010 138, 123-135.e2DOI: (10.1053/j.gastro.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 2 Impact of baseline HCV-RNA level on SVR rates stratified by HCV RNA (<400,000 vs ≥400,000 IU/mL) in (A) HCV mono-infected participants adherent to therapy (n = 48; with genotype available) and (B) HCV/HIV co-infected participants adherent to therapy (n = 29; with genotype available). bl, baseline; vl, viral load. Gastroenterology 2010 138, 123-135.e2DOI: (10.1053/j.gastro.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 3 Impact of estimated duration of infection (≤26 wk, 27–52 wk, and >52 wk) on SVR in HCV (n = 74) and HCV/HIV co-infected (n = 35) participants. Gastroenterology 2010 138, 123-135.e2DOI: (10.1053/j.gastro.2009.09.019) Copyright © 2010 AGA Institute Terms and Conditions